Arlington Capital Partners has announced closing of its sale of Molecular Products to Madison Industries’ vertical, Filtration Group, a leading provider of high-end filtration products. 

Molecular Products is a leading global provider of pure air technologies that protect people, processes, and environments. From removing carbon dioxide during anesthesia to delivering supplemental oxygen backup in critical care situations, the company’s advanced chemical-based technologies fulfill life-critical performance requirements for global customers across numerous end-markets. 

Peter Manos, Managing Partner, Arlington Capital said, “Molecular’s sale to Filtration Group is a testament to the strength of the partnership we have built with management and highlights the strategic value provided to our customers. Over the course of our partnership, we supported nearly $30 million of investment in strategic capital projects, including the build-out of a state of the art facility in Colorado, and completed two complementary acquisitions. These investments drove double-digit annual revenue growth, including greater than 20% growth during the height of the pandemic.” 

“The sale of Molecular to Filtration Group presents a tremendous opportunity for both companies to continue to lead the way in delivering technologies that save lives, protect critical environments, and make the world safer, healthier, and more productive,” said Troy Rhudy, CEO of Molecular. 

Malcolm Little, Partner, Arlington Capital added, “We are thrilled to have found such a strong partner to build upon Molecular’s many successes while delivering an attractive return to Molecular’s stakeholders, a proverbial win-win. Filtration Group’s product expertise and deep customer relationships will provide a strong platform for Molecular’s continued growth. We wish Troy and the entire Molecular team well as they embark on this exciting new partnership.”